Seres Therapeutics, Inc. (NASDAQ:MCRB) to Post Q3 2017 Earnings of ($0.23) Per Share, Leerink Swann Forecasts

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Analysts at Leerink Swann upped their Q3 2017 earnings estimates for shares of Seres Therapeutics in a research report issued to clients and investors on Thursday. Leerink Swann analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($0.23) for the quarter, up from their prior estimate of ($0.73). Leerink Swann also issued estimates for Seres Therapeutics’ Q4 2017 earnings at ($0.74) EPS, FY2017 earnings at ($2.30) EPS, FY2018 earnings at ($2.49) EPS and FY2019 earnings at ($2.24) EPS.

Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright lifted their price objective on Seres Therapeutics from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 3rd. ValuEngine upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, BidaskClub upgraded Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $16.17.

ILLEGAL ACTIVITY NOTICE: “Seres Therapeutics, Inc. (NASDAQ:MCRB) to Post Q3 2017 Earnings of ($0.23) Per Share, Leerink Swann Forecasts” was originally reported by Rincon Hill News and is owned by of Rincon Hill News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://rinconhillneighbors.org/2017/08/19/seres-therapeutics-inc-nasdaqmcrb-to-post-q3-2017-earnings-of-0-23-per-share-leerink-swann-forecasts-updated.html.

Seres Therapeutics (NASDAQ:MCRB) opened at 13.56 on Monday. The firm has a 50-day moving average of $12.20 and a 200-day moving average of $10.57. The company’s market capitalization is $547.69 million. Seres Therapeutics has a one year low of $8.85 and a one year high of $15.09.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. The firm had revenue of $3 million during the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.70) earnings per share.

Several large investors have recently modified their holdings of MCRB. Renaissance Technologies LLC raised its stake in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the biotechnology company’s stock valued at $3,963,000 after buying an additional 103,800 shares during the period. Vanguard Group Inc. raised its stake in shares of Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock valued at $17,645,000 after buying an additional 103,456 shares during the period. Spark Investment Management LLC acquired a new stake in shares of Seres Therapeutics during the first quarter valued at $613,000. JPMorgan Chase & Co. raised its stake in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the period. Finally, American Century Companies Inc. acquired a new stake in shares of Seres Therapeutics during the first quarter valued at $447,000. 75.31% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.